All Stories

  1. Dual plasmepsin IX and X inhibitors are refractory to development of resistance
  2. MK-7602: a potent multi-stage dual-targeting antimalarial
  3. Translation of a Human‐Based Malaria‐on‐a‐Chip Phenotypic Disease Model for In Vivo Applications
  4. The essential malaria protein PfCyRPA targets glycans to invade erythrocytes
  5. 7-N-Substituted-3-oxadiazole Quinolones with Potent Antimalarial Activity Target the Cytochrome bc1 Complex
  6. Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4
  7. The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the Treatment of Malaria
  8. Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362
  9. Substrate Peptidomimetic Inhibitors of P. falciparum Plasmepsin X with Potent Antimalarial Activity
  10. Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax
  11. Property activity refinement of 2-anilino 4-amino substituted quinazolines as antimalarials with fast acting asexual parasite activity
  12. Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity
  13. Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle
  14. Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models
  15. Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody
  16. Generation of monoclonal antibodies against native viral proteins using antigen-expressing mammalian cells for mouse immunization
  17. Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA
  18. Passive Immunoprotection of Plasmodium falciparum-Infected Mice Designates the CyRPA as Candidate Malaria Vaccine Antigen